Research programme: kidney disease therapeutics - Amgen/Galapagos

Drug Profile

Research programme: kidney disease therapeutics - Amgen/Galapagos

Latest Information Update: 08 Sep 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProSkelia
  • Developer Amgen; Galapagos NV
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Kidney disorders

Most Recent Events

  • 08 Sep 2008 Discontinued - Preclinical for Kidney disorders in USA (unspecified route)
  • 22 Dec 2006 Galapagos NV acquires ProStrakan's responsibilities for this research collaboration, as part of Galapagos' purchase of ProSkelia
  • 07 Aug 2006 Preclinical trials in Kidney disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top